P-1199. The burden of respiratory syncytial virus among Brazilian infants (BONSAI study): preliminary results
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1382
Abstract: Abstract Background Respiratory syncytial virus (RSV) is a leading cause of global morbidity and mortality in children < 1 year. Recent data have shown the burden of the disease among full-term babies. RSV surveillance system… read more here.
Keywords: full term; sanofi; term infants; rsv ... See more keywords
P-632. Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.829
Abstract: Abstract Background MenACYW conjugate vaccine (MenACYW-TT) is a quadrivalent meningococcal conjugate vaccine, licensed (MenQuadfi®) for use in children ≥2 years of age in the US. In this modified double-blind, Phase-3 study (NCT03673462) conducted in the… read more here.
Keywords: sanofi stocks; sanofi; group; stocks bonds ... See more keywords
SAT0172 Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csdmards in patients with rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.1373
Abstract: Background: Long-term data are being collected on sarilumab in combination with csDMARDs in patients with RA originally enrolled in six trials (TARGET, NCT01709578; MOBILITY, NCT01061736; NCT01764997; NCT01768572; NCT02057250; NCT01217814) including those who continued into extension… read more here.
Keywords: sanofi; pfizer; treatment; safety ... See more keywords
THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3714
Abstract: Background In the MONARCH Phase 3 randomised controlled trial (RCT) [NCT02332590], sarilumab subcutaneous (SC) 200 mg every 2 weeks (q2w) improved clinical outcomes and multiple aspects of health status/health-related quality of life (HRQoL), as measured by… read more here.
Keywords: shareholder; sanofi; employee; regeneron pharmaceuticals ... See more keywords
SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.3259
Abstract: Background Sarilumab is a human mAb blocking the IL-6Rα, approved for adult patients with moderately to severely active RA. The incidence of Type 2 diabetes is increased in patients with RA, and elevated IL-6 may… read more here.
Keywords: sanofi; sanofi genzyme; sarilumab; glycosylated hemoglobin ... See more keywords
AB1368-HPR ENHANCED ROLE OF NURSES AND OTHER HEALTHCARE PROFESSIONALS (HCPS) IN THE CARE OF RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4284
Abstract: Background Long-term morbidity and mortality in patients with rheumatoid arthritis (RA) are increased(1) due to the increased risk of comorbidities including cardiovascular disease (40-70% incidence(2); 5-12.9% prevalence(3)), diabetes (IR of 8.6 per 1000 person-years(4); 20%(5)),… read more here.
Keywords: none declared; sanofi; pfizer; eli lilly ... See more keywords
THU0579 “EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICE
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1219
Abstract: The eRA (evolving the management of RA) programme was initiated in Europe to provide practical educational tools that address unmet needs in the management of rheumatoid arthritis (RA). Several eRA tools – covering early access… read more here.
Keywords: sanofi; roche; consultant; support ... See more keywords
AB0301 SARILUMAB AS MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 12-WEEK TREATMENT RESULTS FROM A MULTICENTER, OPEN-LABEL, PROSPECTIVE, SINGLE-ARM OBSERVATIONAL STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1972
Abstract: Background: Due to strict inclusion/exclusion criteria, randomized controlled trials (RCTs) may not represent the heterogeneous rheumatoid arthritis (RA) population encountered in routine clinical practice; longitudinal observational studies are needed to complement learnings from RCTs. The… read more here.
Keywords: sanofi; combination; treatment; genzyme ... See more keywords
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1977
Abstract: Background: Sarilumab is a human interleukin (IL)-6 receptor inhibitor approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The relationship between disease activity (DA), sarilumab treatment, and improvements in patient-reported… read more here.
Keywords: sanofi; roche; sanofi genzyme; eli lilly ... See more keywords
THU0197 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2396
Abstract: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized, double-blind, controlled trials across a spectrum of rheumatoid arthritis (RA) patients… read more here.
Keywords: sanofi; abbvie; bristol myers; exposure ... See more keywords
SAT0608-HPR EULAR POINTS TO CONSIDER FOR THE DETECTION, ASSESSMENT AND MANAGEMENT OF NON-ADHERENCE IN PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.787
Abstract: Background: Non-adherence to medication and non-pharmacological interventions precludes reaching an optimal outcome. 30 to 80% of patients with rheumatic and musculoskeletal diseases (RMDs) do not adhere to their recommended treatment regimens. Objectives: The objective of… read more here.
Keywords: grant research; sanofi; support; research support ... See more keywords